RU96120415A - ANTITASCULAR COMPOSITION CONTAINING ANTITASCULAR AGENT AND BENZIDAMINE - Google Patents

ANTITASCULAR COMPOSITION CONTAINING ANTITASCULAR AGENT AND BENZIDAMINE

Info

Publication number
RU96120415A
RU96120415A RU96120415/14A RU96120415A RU96120415A RU 96120415 A RU96120415 A RU 96120415A RU 96120415/14 A RU96120415/14 A RU 96120415/14A RU 96120415 A RU96120415 A RU 96120415A RU 96120415 A RU96120415 A RU 96120415A
Authority
RU
Russia
Prior art keywords
pharmaceutically acceptable
composition according
acceptable salt
benzidamine
dextromethorphan
Prior art date
Application number
RU96120415/14A
Other languages
Russian (ru)
Other versions
RU2143901C1 (en
Inventor
Галли Анджели Депальмо
Original Assignee
Ацьенде Кимике Pьюните Анджелини Франческо А.К.Р.А.Ф. С.п.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI940362A external-priority patent/IT1274026B/en
Application filed by Ацьенде Кимике Pьюните Анджелини Франческо А.К.Р.А.Ф. С.п.А. filed Critical Ацьенде Кимике Pьюните Анджелини Франческо А.К.Р.А.Ф. С.п.А.
Publication of RU96120415A publication Critical patent/RU96120415A/en
Application granted granted Critical
Publication of RU2143901C1 publication Critical patent/RU2143901C1/en

Links

Claims (8)

1. Противокашлевая фармацевтическая композиция для перорального введения, отличающаяся тем, что она обеспечивает значительный контакт ее компонентов со слизистыми оболочками защечной полости и содержит центрально действующее противокашлевое средство или его фармацевтически приемлемую соль с кислотой.1. An antitussive pharmaceutical composition for oral administration, characterized in that it provides significant contact of its components with the mucous membranes of the buccal cavity and contains a centrally acting antitussive agent or a pharmaceutically acceptable salt thereof with an acid. 2. Композиция по п.1, отличающаяся тем, что она имеет форму пастилок, леденцов, жевательных таблеток или жевательных резинок. 2. The composition according to claim 1, characterized in that it has the form of lozenges, lozenges, chewable tablets or chewing gums. 3. Композиция по п.1 или 2, отличающаяся тем, что она содержит от 0,5 до двойной стандартной дозы центрально действующего противокашлевого средства, выбираемого из группы, состоящей из кодеина, декстрометорфана, дигидрокодеина, димеморфана, носкапина, левопропоксифена напсилата, карбетапентана, карамифена, хлофедианола, дифенидрамина, глауцина, бензонатата, гидрокодона, гидроморфона и их фармацевтически приемлемых солей. 3. The composition according to claim 1 or 2, characterized in that it contains from 0.5 to a double standard dose of a centrally acting antitussive agent selected from the group consisting of codeine, dextromethorphan, dihydrocodeine, dimemorphan, noscapine, levopropoxyphene napsilate, carbetapentane, karamifen, chlorofedianol, diphenidramine, glaucin, benzonate, hydrocodone, hydromorphone and their pharmaceutically acceptable salts. 4. Композиция по любому одному из пп.1-3, отличающаяся тем, что она содержит количество бензидамина, равное от 1/200 до двойного количества (по весу) центрально действующего противокашлевого средства или эквивалентное количество его фармацевтически приемлемой соли с кислотой. 4. The composition according to any one of claims 1 to 3, characterized in that it contains an amount of benzidamine equal to from 1/200 to double the amount (by weight) of the centrally acting antitussive agent or an equivalent amount of its pharmaceutically acceptable salt with an acid. 5. Композиция по п.1, отличающаяся тем, что она содержит от 0,15 до 10 мг бензидамина и от 5 до 30 мг декстрометорфана или эквивалентные количества их фармацевтически приемлемой соли. 5. The composition according to claim 1, characterized in that it contains from 0.15 to 10 mg of benzidamine and from 5 to 30 mg of dextromethorphan or equivalent amounts of a pharmaceutically acceptable salt thereof. 6. Композиция по п.5, отличающаяся тем, что фармацевтически приемлемой солью бензидамина является гидрохлорид. 6. The composition according to claim 5, characterized in that the pharmaceutically acceptable salt of benzidamine is hydrochloride. 7. Композиция по п.5 или 6, отличающаяся тем, что фармацевтически приемлемой солью декстрометорфана является гидробромид. 7. The composition according to claim 5 or 6, characterized in that the pharmaceutically acceptable salt of dextromethorphan is hydrobromide. 8. Композиция по п. 5 или 6, отличающаяся тем, что фармацевтически приемлемой солью декстрометорфана является гидрат гидробромида. 8. The composition according to p. 5 or 6, characterized in that the pharmaceutically acceptable salt of dextromethorphan is hydrobromide hydrate.
RU96120415A 1994-03-01 1995-02-22 Antibechic composition containing antibechic agent and benzidamine RU2143901C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI940362A IT1274026B (en) 1994-03-01 1994-03-01 ANTITOSSE COMPOSITION
ITMI94A000362 1994-03-01
PCT/EP1995/000658 WO1995023602A1 (en) 1994-03-01 1995-02-22 Antitussive composition containing an antitussive and benzydamine

Publications (2)

Publication Number Publication Date
RU96120415A true RU96120415A (en) 1998-12-27
RU2143901C1 RU2143901C1 (en) 2000-01-10

Family

ID=11368015

Family Applications (1)

Application Number Title Priority Date Filing Date
RU96120415A RU2143901C1 (en) 1994-03-01 1995-02-22 Antibechic composition containing antibechic agent and benzidamine

Country Status (27)

Country Link
US (1) US5932589A (en)
EP (1) EP0748222B1 (en)
JP (1) JP3348858B2 (en)
KR (1) KR970701047A (en)
CN (1) CN1088358C (en)
AT (1) ATE195074T1 (en)
AU (1) AU681257B2 (en)
BR (1) BR9506956A (en)
CA (1) CA2184594C (en)
CZ (1) CZ284798B6 (en)
DE (1) DE69518229T2 (en)
DK (1) DK0748222T3 (en)
ES (1) ES2149969T3 (en)
FI (1) FI963394A (en)
GR (1) GR3034665T3 (en)
HU (1) HUT75937A (en)
IT (1) IT1274026B (en)
NO (1) NO309965B1 (en)
NZ (1) NZ281230A (en)
PL (1) PL178608B1 (en)
PT (1) PT748222E (en)
RO (1) RO117147B1 (en)
RU (1) RU2143901C1 (en)
SK (1) SK282567B6 (en)
UA (1) UA37278C2 (en)
WO (1) WO1995023602A1 (en)
ZA (1) ZA951588B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124282A (en) * 1997-05-22 2000-09-26 Sellers; Edward M. Drug formulations
PT1041987E (en) * 1997-12-22 2006-07-31 Euro Celtique Sa PHARMACEUTICAL FORM OF ORAL DOSAGE, UNDERSTANDING A COMBINATION OF AN AGRONIST OF OPIOIDE AND NALTREXONE
US7138133B2 (en) 2001-10-10 2006-11-21 The Procter & Gamble Company Orally administered liquid compositions
AU2003219348A1 (en) * 2002-04-22 2003-11-03 Adcock Ingram Intellectual Property (Proprietary) Limited Pharmaceutical compositions comprising a decongenstant and further active ingredients for treating cough and flu
DE602005020359D1 (en) * 2005-01-14 2010-05-12 Camurus Ab TOPICAL BIOADHESIVE FORMULATIONS
CA2594710C (en) * 2005-01-14 2011-01-25 Camurus Ab Topical bioadhesive formulations
CN101219140B (en) * 2007-12-24 2011-06-01 重庆市莱美药物技术有限公司 Benzydamine Hcl soluble tablet and method for preparing the same
ES2554332T3 (en) 2009-07-08 2015-12-18 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Use of benzydamine in the treatment of p40 dependent diseases
KR102290178B1 (en) * 2013-03-13 2021-08-18 트리스 파마 인코포레이티드 Benzonatate modified release solid tablets and capsules
EP3256459B1 (en) * 2015-02-09 2022-07-13 Cellixbio Private Limited Compositions and methods for the treatment of mucositis
US11214544B2 (en) 2017-04-14 2022-01-04 Kempharm, Inc. Dextrorphan prodrugs and processes for making and using them

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0555411A1 (en) * 1990-10-31 1993-08-18 The Procter & Gamble Company Dextromethorphan antitussive compositions
US5196436A (en) * 1990-10-31 1993-03-23 The Procter & Gamble Company Dextromethorphan antitussive compositions

Similar Documents

Publication Publication Date Title
US5869498A (en) Pain alleviating drug composition and method for alleviating pain
US5196436A (en) Dextromethorphan antitussive compositions
KR101326206B1 (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption
ES2729679T3 (en) Morphinan derivatives for the treatment of drug overdose
IL149496A (en) Pharmaceutical combinations and their use in treating gastrointestinal disorders
RU96120415A (en) ANTITASCULAR COMPOSITION CONTAINING ANTITASCULAR AGENT AND BENZIDAMINE
US5622980A (en) Oral compositions of H2-antagonists
KR970701047A (en) ANTITUSSIVE COMPOSITION CONTAINING AN ANTITUS SIVE AND BENZYDAMINE
JP2575569B2 (en) Use of glycine / NMDA receptor ligand for the treatment of drug dependence and withdrawal symptoms
WO1991018606A3 (en) Orally active nonaddicting analgesics
US20050053656A1 (en) Compositions and methods for treating pain
CA2129676C (en) Dextromethorphan antitussive compositions
US3755586A (en) Anti tussive compositions containing piperidine derivatives
RU2003135201A (en) APPLICATION OF THE NALTREXONE OPIOID ANTAGONIST FOR THE PREVENTION AND CONTROL OF ADVERSE EFFECTS CAUSED BY OPIOIDS
WO1994020074A1 (en) Adsorbate compositions
US20070248667A1 (en) Tannate Compositions and Methods of Use
MXPA96003747A (en) Antitus composition
MXPA96006041A (en) Dosage form of rapida disoluc